May 29 (Reuters) - Merck ( MRK ) and Japan-based Daiichi
Sankyo ( DSKYF ) said on Thursday they have withdrawn the U.S.
application for an experimental lung cancer treatment, which
belongs to a lucrative class of cancer therapies that work like
"guided missiles".